Free Trial

UiPath (NYSE:PATH) CEO Daniel Dines Sells 45,000 Shares

UiPath logo with Computer and Technology background
Image from MarketBeat Media, LLC.

Key Points

  • UiPath CEO Daniel Dines sold 45,000 shares on Dec. 12 at $17.91, part of a string of identical 45,000-share sales in Oct–Dec; his ownership fell 0.15% to about 29,018,585 shares valued near $519.7 million.
  • UiPath recently beat quarterly estimates (EPS $0.16 vs. $0.14; revenue $411.11M, +15.9% YoY) while the stock trades around $16.13 and carries a consensus analyst rating of "Hold" with a $16.00 target.
  • Interested in UiPath? Here are five stocks we like better.

UiPath, Inc. (NYSE:PATH - Get Free Report) CEO Daniel Dines sold 45,000 shares of the firm's stock in a transaction on Friday, December 12th. The shares were sold at an average price of $17.91, for a total transaction of $805,950.00. Following the completion of the transaction, the chief executive officer directly owned 29,018,585 shares of the company's stock, valued at $519,722,857.35. This represents a 0.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Daniel Dines also recently made the following trade(s):

  • On Monday, December 15th, Daniel Dines sold 45,000 shares of UiPath stock. The shares were sold at an average price of $17.30, for a total transaction of $778,500.00.
  • On Wednesday, December 10th, Daniel Dines sold 45,000 shares of UiPath stock. The stock was sold at an average price of $18.61, for a total transaction of $837,450.00.
  • On Monday, December 8th, Daniel Dines sold 45,000 shares of UiPath stock. The shares were sold at an average price of $19.21, for a total transaction of $864,450.00.
  • On Wednesday, November 5th, Daniel Dines sold 45,000 shares of UiPath stock. The stock was sold at an average price of $15.07, for a total value of $678,150.00.
  • On Monday, November 3rd, Daniel Dines sold 45,000 shares of UiPath stock. The shares were sold at an average price of $16.23, for a total value of $730,350.00.
  • On Friday, October 31st, Daniel Dines sold 45,000 shares of UiPath stock. The stock was sold at an average price of $15.72, for a total value of $707,400.00.
  • On Wednesday, October 29th, Daniel Dines sold 45,000 shares of UiPath stock. The shares were sold at an average price of $16.29, for a total value of $733,050.00.
  • On Monday, October 27th, Daniel Dines sold 45,000 shares of UiPath stock. The stock was sold at an average price of $16.73, for a total transaction of $752,850.00.
  • On Friday, October 24th, Daniel Dines sold 45,000 shares of UiPath stock. The shares were sold at an average price of $15.46, for a total transaction of $695,700.00.
  • On Wednesday, October 22nd, Daniel Dines sold 45,000 shares of UiPath stock. The stock was sold at an average price of $15.53, for a total transaction of $698,850.00.

UiPath Stock Performance

PATH traded down $1.30 on Monday, reaching $16.13. The company had a trading volume of 23,709,137 shares, compared to its average volume of 15,560,561. The stock has a market cap of $8.62 billion, a P/E ratio of 38.39, a P/E/G ratio of 5.19 and a beta of 1.10. UiPath, Inc. has a fifty-two week low of $9.38 and a fifty-two week high of $19.84. The company's fifty day moving average is $15.48 and its 200 day moving average is $13.29.

UiPath (NYSE:PATH - Get Free Report) last issued its quarterly earnings data on Wednesday, December 3rd. The company reported $0.16 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.14 by $0.02. The company had revenue of $411.11 million during the quarter, compared to analysts' expectations of $392.46 million. UiPath had a return on equity of 3.73% and a net margin of 14.79%.The business's revenue was up 15.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.11 earnings per share. On average, sell-side analysts expect that UiPath, Inc. will post -0.17 EPS for the current year.

Institutional Investors Weigh In On UiPath

Hedge funds and other institutional investors have recently bought and sold shares of the company. Twin Peaks Wealth Advisors LLC bought a new position in UiPath in the second quarter valued at about $28,000. AdvisorNet Financial Inc increased its holdings in UiPath by 320.4% in the second quarter. AdvisorNet Financial Inc now owns 2,476 shares of the company's stock valued at $32,000 after purchasing an additional 1,887 shares during the period. GAMMA Investing LLC raised its position in UiPath by 48.0% during the 2nd quarter. GAMMA Investing LLC now owns 2,989 shares of the company's stock worth $38,000 after purchasing an additional 969 shares during the last quarter. IFP Advisors Inc grew its position in shares of UiPath by 508.0% in the 2nd quarter. IFP Advisors Inc now owns 3,283 shares of the company's stock valued at $42,000 after buying an additional 2,743 shares during the last quarter. Finally, Bayforest Capital Ltd increased its stake in shares of UiPath by 852.4% in the second quarter. Bayforest Capital Ltd now owns 4,143 shares of the company's stock valued at $53,000 after buying an additional 3,708 shares during the period. Institutional investors own 62.50% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Canaccord Genuity Group boosted their target price on shares of UiPath from $15.00 to $19.00 and gave the company a "buy" rating in a research report on Thursday, December 4th. Truist Financial set a $17.00 target price on shares of UiPath in a research report on Thursday, December 4th. Wells Fargo & Company boosted their price target on UiPath from $12.00 to $14.00 and gave the company an "equal weight" rating in a research note on Thursday, December 4th. Weiss Ratings raised UiPath from a "sell (d+)" rating to a "hold (c)" rating in a report on Tuesday, December 9th. Finally, Royal Bank Of Canada boosted their target price on shares of UiPath from $16.00 to $19.00 and gave the company a "sector perform" rating in a research report on Wednesday, December 10th. One research analyst has rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, UiPath currently has an average rating of "Hold" and a consensus target price of $16.00.

Read Our Latest Research Report on PATH

About UiPath

(Get Free Report)

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.

Featured Articles

Insider Buying and Selling by Quarter for UiPath (NYSE:PATH)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in UiPath Right Now?

Before you consider UiPath, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UiPath wasn't on the list.

While UiPath currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginner's Guide To Retirement Stocks Cover

Click the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Related Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines